% | $
Quotes you view appear here for quick access.

Boston Scientific Corporation Message Board

  • ahtawil ahtawil Dec 23, 1997 9:31 PM Flag

    bsx in trouble, $25 to $30

    with avei's approval, market shares are evaporating fast !! bsx will be going down to $25 to $30

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Perhaps the share price of BSX will drop, but not because of AVE. BSX does not have a stent approved in the US yet, so there is no "market share" to evaporate in this regard. And AVE does not sell stand alone balloons in the US. As a stretch, it does not appear that AVE stents need a "post dilatation" balloon, so BSX may lose some of that market (as will any other "high pressure" balloon makers that sell into the post-dilatation market).

      GDT stent and balloon systems have seen a huge uptake in the last several months. I would imagine BSX is losing some balloon market to this situation. And Cordis' Charger has come onstream to great reviews.

      Until BSX has a stent approved in the US (PMA is supposed to be submitted right around now, then add 6 months to that as an estimate, although AVE only took 140 days, and GDT even less), then it won't lose stent market share in the US.

23.59+0.29(+1.24%)10:53 AMEDT